Table 2.
Conjugate strategies for therapeutic CO release.
| Sr. # | CORMats | Therapeutic Implications | Refs |
|---|---|---|---|
| 1 | Micellization | Bioactive in a murine model of inflammatory colitis; potential for curing the ROS affected inflammatory disease; In response to human monocytes and attenuates the LPS-induced inflammatory. | [55,59,145] |
| 2 | Proteins | Regulation the cytokines IL-6 and IL-10; artificial metallohydrolase performance and elevated NF-κB factor (10 folds). | [121,146,147,148,149] |
| 3 | Vitamins | Shows HO-1 expression; inducing nuclear accumulation of Nrf2; antimalarial drug artesunate and acute liver failure. | [150,151,152,153] |
| 4 | Polymers | HCT116 human colon cancer and HepG2 liver cancer cells; enhance the EPR effect and targeting the tumor sites; achieve special and selective physiological targets. | [47,154,155,156] |
| 5 | Porous structure materials | Inflammatory skin issues and topical skin cancer treatment. Surprisingly, no toxicity was found in mouse fibroblast 3T3 cells. | [50,111]. |
| 6 | Nanoparticles | Cysteine and subdues feedback to pro-inflammatory mediator’s IL-6; cardiovascular therapy and relax the rat aorta muscle rings. | [157,168] |
| 7 | Peptide | Human prostate cancer cell line (PC-3) and supported cardiomyocyte viability. | [139,140,141,142,143,144] |
| 8 | Nano-sheets | Controllable CO release (e.g. GO-MnCORMats) suitable for inflammatory diseases after LPS stimulation and responsive intracellular CO release. | [48] |
| 9 | Nano-diamond | Nano-diamond precursor compatible with photons, hopefully, could be modified for special cell targeting. | [159] |
| 10 | MOFs | Inflammatory bowel disease and expected pharmacological applications by downsizing the MOF crystals to the nanoscale. | [137,138] |
| 11 | Metallodendrimers | Potential for inflammatory disease and cancer cells. | [161] |